Pharmafile Logo
Pharmafocus logo
Advanced Search

M&A

Showing 15 posts of 45 posts found.

2017

Seven pharma trends for 2017

December 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing

What will be the key industry trends in 2017?Industry uncertaintyPerhaps the biggest hallmark of 2016-going-into-2017 is the sense of hesitation …

Feature

Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal

July 6, 2016
Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer

Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …

News
merckincweb2

Merck & Co agrees to buy biotech firm Afferent for upfront $500 million in cash

June 10, 2016
Medical Communications, Sales and Marketing Afferent Pharmaceuticals, Financial, M&A, MA, Merck & Co

US drugmaker Merck & Co (NYSE: MRK) said it has agreed to buy biotech firm Afferent Pharmaceuticals for an upfront …

News

Monsanto rejects Bayer’s $62 billion offer

May 25, 2016
Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto

World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) …

News
sanofi_pasteur_scientist

Sanofi Files Hart-Scott-Rodino notification for Medivation acquisition

May 13, 2016
Medical Communications, Sales and Marketing M&A, MA, Medivation, Sanofi, deal

French drugmaker Sanofi (Euronext: SAN) on Friday said it has filed a premerger notification with the US Department of Justice Antitrust …

News
medivation

Medivation maybe mulling sale as bidding race heats up – Reports

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …

News
amgen_flag

Amgen looking to join the fray, mulling Medivation bid – Reports

May 5, 2016
Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …

News

Pfizer joins the race, bids for Medivation – Reports

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …

News

Sanofi makes unsolicited $9.8 billion bid for Medivation

April 28, 2016
Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer

French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …

News
eli_lilly_logo

Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump

April 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis

Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …

News
jj_sign_on_wall

Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million

April 6, 2016
Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research

Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …

News
gilead-sciences

Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions

Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …

News
sunpharma

Sun Pharma forays into Japan with $293 million product buy from Novartis

March 30, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Japan, M&A, MA, Novartis, Sun Pharma, generics

Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the …

News

TREND: Rare disease, cancer drugs will drive pharma M&A’s, growth

March 29, 2016
Manufacturing and Production, Research and Development, Sales and Marketing M&A, MA, Orphan Drugs, cancer drugs

Moody’s Investor Service lowered its growth outlook for the global pharma sector but maintained the mergers and acquisitions in the …

Feature
teva_copy

Teva says closing buy of Allergan’s generics biz may take longer

March 16, 2016
Business Services, Research and Development, Sales and Marketing Allergan, M&A, MA, Pfizer, Teva

Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) said its $40.5 billion acquisition of Allergan’s generics business will take longer than expected, …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026